Bcl-2 phosphorylation in a human breast carcinoma xenograft: A common event in response to effective DNA-damaging drugs

Biochemical Pharmacology

Volumn 60, Issue 1, 2000, Pages 77-82

  Pratesi, Graziella ^a   Polizzi, Donatella ^a   Perego, Paola ^a   Dal Bo, Laura ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracycline; Apoptosis; Bcl 2; Cisplatin; Taxane; Tumor xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3464; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ORTATAXEL; PACLITAXEL; PROTEIN BCL 2; SABARUBICIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DNA DAMAGE; FEMALE; HUMANS; MICE; MICE, NUDE; MICROTUBULES; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034055659     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00300-2     Document Type: Article

References (23)

1. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
2. Vaux D., Cory S., Adams J. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 335:1988;440-442.
3. Reed J.C., Cuddy M., Haldar S., Croce C., Nowell P., Makover D., Bradley K. BCL-2-mediated tumorigenicity of a human T-lymphoid cell line Synergy with MYC and inhibition by BCL2 antisense . Proc Natl Acad Sci U S A. 87:1990;3660-3664.
4. Reed J.C., Stein S., Subasinghe C., Haldar C., Croce C.M., Yum S., Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides . Cancer Res. 50:1990;6565-6570.
5. Campos L., Roualult J.P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Magaud J.P., Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 18:1993;3091-3096.
6. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 92:1995;4507-4511.
7. Alnemri E.S., Robertson N.M., Fernandes T.F., Croce C.M., Litwack G. Overexpressed full-length human BCL2 extends the survival of baculovirus-infected Sf9 insect cells. Proc Natl Acad Sci USA. 89:1992;7295-7299.
8. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56:1996;1253-1255.
9. Haldar S., Basu A., Croce C.M. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
10. De Cesare M., Pratesi G., Giusti A., Polizzi D., Zunino F. Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts. Br J Cancer. 77:1998;434-439.
11. Reed J.C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 7:1995;541-546.
12. Zunino F., Perego P., Pilotti S., Pratesi G., Supino R., Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther. 76:1997;177-185.
13. Pratesi G., De Cesare M., Zunino F. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft. Cancer Chemother Pharmacol. 38:1996;123-128.
14. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., Embleton J., Newell D., Raymond R., Stables J., Stephens T., Wallace J. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 77:1998;1-10.
15. Arcamone F., Animati F., Berettoni M., Bigioni M., Capranico G., Casazza A.M., Caserini C., Cipollone A., De Cesare M., Franciotti M., Lombardi P., Madami A., Manzini S., Monteagudo E., Polizzi D., Pratesi G., Righetti S.C., Salvatore C., Supino R., Zunino F. Doxorubicin disaccharide analogue Apoptosis-related improvement of efficacy in vivo . J Natl Cancer Inst. 89:1997;1217-1223.
16. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
17. Gajewski T.F., Thompson C.B. Apoptosis meets signal transduction Elimination of a BAD influence . Cell. 87:1996;589-592.
18. Gasparini G., Barbareschi M., Doglioni C., Palma P.D., Mauri F.A., Boracchi P., Bevilacqua P., Caffo O., Morelli L., Verderio P., Pezzella F., Harris A.L. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1:1995;189-198.
19. Ling Y.H., Tornos C., Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem. 273:1998;18984-18991.
20. Scatena C.D., Stewart Z.A., Mays D., Tang L.J., Keefer O., Leach S.D., Pietenpol J.A. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem. 273:1998;30777-30784.
21. Pratesi G., Perego P., Polizzi D., Righetti S.C., Supino R., Caserini C., Manzotti C., Giuliani F.C., Pezzoni G., Tognella S., Spinelli S., Farrell N., Zunino F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours Hypersensitivity of p53-mutant human tumour xenografts . Br J Cancer. 80:1999;1912-1919.
22. Perego P., Caserini C., Gatti L., Carenini N., Romanelli S., Supino R., Colangelo D., Viano I., Leone R., Spinelli S., Pezzoni G., Manzotti C., Farrell N., Zunino F. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol. 55:1999;528-534.
23. Milross C.G., Mason K.A., Hunter N.R., Chung W.K., Peters L.J., Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 88:1996;1308-1314.